Drug interactions
Ruxolitinib + Ublituximab
Severity: Moderate
Ruxolitinib and Ublituximab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both agents impair immune function, and combined use may increase the risk of serious or opportunistic infections. Ublituximab depletes B cells for an extended period.
What this interaction means in plain words
Ruxolitinib and Ublituximab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Ruxolitinib belongs to Oncology; Ublituximab belongs to Miscellaneous.
Why it happens
Additive immunosuppression through JAK inhibition and anti-CD20 B-cell depletion.
What to do
Screen for hepatitis B and other infections before use, and monitor for infection throughout, treating promptly.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Ruxolitinib and Ublituximab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Ruxolitinib
Other interactions of Ublituximab
Frequently asked questions
Can I take Ruxolitinib with Ublituximab?
MediHelp rates the interaction as moderate. Ruxolitinib and Ublituximab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Both agents impair immune function, and combined use may increase the risk of serious or opportunistic infections. Ublituximab depletes B cells for an extended period.
How serious is the interaction between Ruxolitinib and Ublituximab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Screen for hepatitis B and other infections before use, and monitor for infection throughout, treating promptly.
What other medicines interact with Ruxolitinib?
MediHelp also lists interactions of Ruxolitinib with, for example, Atazanavir, Ceritinib, Chloramphenicol. The full list is on the Ruxolitinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
